Select Publications
Journal articles
2020, 'Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction', Journal of the American College of Cardiology, 76, pp. 2076 - 2085, http://dx.doi.org/10.1016/j.jacc.2020.09.004
,2020, 'Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial', The Lancet Diabetes and Endocrinology, 8, pp. 903 - 914, http://dx.doi.org/10.1016/s2213-8587(20)30300-4
,2020, 'Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 2199 - 2203, http://dx.doi.org/10.1111/dom.14143
,2020, 'Seventeen-year associations between diet quality defined by the health star rating and mortality in australians: The australian diabetes, obesity and lifestyle study (ausdiab)', Current Developments in Nutrition, 4, pp. nzaa157 - nzaa157, http://dx.doi.org/10.1093/cdn/nzaa157
,2020, 'The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program', International Journal of Cardiology, 318, pp. 126 - 129, http://dx.doi.org/10.1016/j.ijcard.2020.06.011
,2020, 'Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program', Journal of the American Society of Nephrology, 31, pp. 2446 - 2456, http://dx.doi.org/10.1681/ASN.2019121312
,2020, 'Estimated 24-Hour Urinary Sodium Excretion and Incident Cardiovascular Disease and Mortality among 398628 Individuals in UK Biobank', Hypertension, 76, pp. 683 - 691, http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14302
,2020, 'Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes', Kidney International, 98, pp. 769 - 777, http://dx.doi.org/10.1016/j.kint.2020.04.051
,2020, 'Prospective associations of four nutrient profiles with weigh gain, overweight and obesity risk', European Journal of Public Health, 30, pp. V1009 - V1009, http://dx.doi.org/10.1093/eurpub/ckaa166.1285
,2020, 'Impact of salt substitute and stepwise reduction of salt supply on blood pressure in residents in senior residential facilities: Design and rationale of the DECIDE-Salt trial', American Heart Journal, 226, pp. 198 - 205, http://dx.doi.org/10.1016/j.ahj.2020.05.013
,2020, 'Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a double-blinded, randomized-controlled trial', Journal of Clinical Hypertension, 22, pp. 1504 - 1512, http://dx.doi.org/10.1111/jch.13947
,2020, 'The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis', Progress in Cardiovascular Diseases, 63, pp. 518 - 524, http://dx.doi.org/10.1016/j.pcad.2020.04.008
,2020, 'Effects of allopurinol on the progression of chronic kidney disease', New England Journal of Medicine, 382, pp. 2504 - 2513, http://dx.doi.org/10.1056/NEJMoa1915833
,2020, 'Contribution of major food companies and their products to household dietary sodium purchases in Australia', International Journal of Behavioral Nutrition and Physical Activity, 17, pp. 81, http://dx.doi.org/10.1186/s12966-020-00982-z
,2020, '27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or
,2020, 'Is salt substitution ready for prime time?', Nature Reviews Cardiology, 17, pp. 325 - 326, http://dx.doi.org/10.1038/s41569-020-0365-0
,2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013
,2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019
,2020, 'The effects of a supermarket-based intervention on the nutritional quality of private-label foods: A prospective study', Nutrients, 12, pp. 1 - 16, http://dx.doi.org/10.3390/nu12061692
,2020, 'Uptake of australia’s health star rating system 2014–2019', Nutrients, 12, pp. 1 - 13, http://dx.doi.org/10.3390/nu12061791
,2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091
,2020, 'A Systematic Review of the Sources of Dietary Salt Around the World', Advances in Nutrition, 11, pp. 677 - 686, http://dx.doi.org/10.1093/advances/nmz134
,2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168
,2020, 'Reply: Mediators of the Effects of Canagliflozin on Heart Failure: Central Role of the Cardiorenal Axis', JACC: Heart Failure, 8, pp. 427, http://dx.doi.org/10.1016/j.jchf.2020.02.005
,2020, 'Salt-related knowledge, attitudes and behaviors (KABS) among victorian adults following 22-months of a consumer awareness campaign', Nutrients, 12, pp. 1216, http://dx.doi.org/10.3390/nu12051216
,2020, 'Sex disparities in cardiovascular outcome trials of populations with diabetes: A Systematic Review and Meta-analysis', Diabetes Care, 43, pp. 1157 - 1163, http://dx.doi.org/10.2337/dc19-2257
,2020, 'Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: Modelling study', The BMJ, 369, pp. m824, http://dx.doi.org/10.1136/bmj.m824
,2020, 'A Novel Cardioprotective Therapy That Also Improves Glycemia', JAMA - Journal of the American Medical Association, 323, pp. 1349 - 1350, http://dx.doi.org/10.1001/jama.2020.1905
,2020, 'A comparison of the nutritional qualities of supermarket’s own and regular brands of bread in sweden', Nutrients, 12, pp. 1162, http://dx.doi.org/10.3390/nu12041162
,2020, 'Changes in sodium levels of processed foods among the International Food and Beverage Association member companies in Australia: 2013–2017', Journal of Food Composition and Analysis, 87, pp. 103405, http://dx.doi.org/10.1016/j.jfca.2019.103405
,2020, 'Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 530 - 539, http://dx.doi.org/10.1111/dom.13920
,2020, 'Interim effects of salt substitution on urinary electrolytes and blood pressure in the China Salt Substitute and Stroke Study (SSaSS)', American Heart Journal, 221, pp. 136 - 145, http://dx.doi.org/10.1016/j.ahj.2019.12.020
,2020, 'Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017', The Lancet, 395, pp. 709 - 733, http://dx.doi.org/10.1016/S0140-6736(20)30045-3
,2020, 'Effect of dose and duration of reduction in dietary sodium on blood pressure levels: Systematic review and meta-analysis of randomised trials', The BMJ, 368, pp. m315, http://dx.doi.org/10.1136/bmj.m315
,2020, 'A Community-Based Intervention for Managing Hypertension in Rural South Asia.', New England Journal of Medicine, 382, pp. 717 - 726, http://dx.doi.org/10.1056/nejmoa1911965
,2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial', Circulation, 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359
,2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908
,2020, 'Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men', Diabetes, Obesity and Metabolism, 22, pp. 263 - 266, http://dx.doi.org/10.1111/dom.13876
,2020, 'Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes', JACC: Heart Failure, 8, pp. 57 - 66, http://dx.doi.org/10.1016/j.jchf.2019.08.004
,2020, 'Sources of dietary sodium and implications for a state-wide salt reduction program in Victoria, Australia', British Journal of Nutrition, 123, pp. 1165 - 1175, http://dx.doi.org/10.1017/S000711452000032X
,2020, 'Measuring the healthiness of child-targeted cereals: a study of the FoodSwitch platform in Sweden', Journal of Medical Internet Research, http://dx.doi.org/10.2196/preprints.17780
,2020, 'THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL', Journal of the American College of Cardiology, 75, pp. 674, http://dx.doi.org/10.1016/s0735-1097(20)31301-2
,2019, 'Front-of-pack nutrition labelling to promote healthier diets: Current practice and opportunities to strengthen regulation worldwide', BMJ Global Health, 4, pp. e001882, http://dx.doi.org/10.1136/bmjgh-2019-001882
,2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, 1, pp. e220 - e228, http://dx.doi.org/10.1016/S2665-9913(19)30078-5
,2019, 'Do GLP-1 receptor agonists care if you have heart failure?', Circulation, 140, pp. 1623 - 1625, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.043303
,2019, 'A comparison of the healthiness of packaged foods and beverages from 12 countries using the Health Star Rating nutrient profiling system, 2013–2018', Obesity Reviews, 20, pp. 107 - 115, http://dx.doi.org/10.1111/obr.12879
,2019, 'Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: The Survey of PatIents with treatment ResIstant hyperTension study', Journal of Hypertension, 37, pp. 2216 - 2224, http://dx.doi.org/10.1097/HJH.0000000000002184
,2019, 'SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 7, pp. 845 - 854, http://dx.doi.org/10.1016/S2213-8587(19)30256-6
,2019, 'Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program', Diabetologia, 62, pp. 1854 - 1867, http://dx.doi.org/10.1007/s00125-019-4955-5
,2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial', Circulation, 140, pp. 739 - 750, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007
,